Agenda Item No.:

382.1

PALM BEACH COUNTY BOARD OF COUNTY COMMISSIONERS

AGENDA ITEM SUMMARY Meeting Date: December 19, 2017 (X) Consent () Regular () Ordinance () Public Hearing Department Submitted By: Medical Examiner's Office Submitted For: Medical Examiner's Office

I. EXECUTIVE BRIEF

Motion and Title: Staff Recommends Motion to Approve: Contract with AXIS Forensic Toxicology, Inc. to provide forensic toxicology testing for the period January 1, 2018 through December 31, 2020 in an amount not to exceed \$975,000.

Summary: The AXIS Forensic Toxicology, Inc. contract includes various drug detection panels that provide statutorily required and necessary complex toxicology testing as economically as possible. The costs of the comprehensive, drugs of abuse (extended), and drugs of abuse are \$210, \$175, and \$125 respectively (see fee schedule Attachment "B"). Each drug panel involves the detection and quantitation of volatiles (alcohol) and drugs listed in Attachment "C" in blood, urine and vitreous fluid from the submitted Medical Examiner case. Additional tests for carbon monoxide, vitreous chemistry, and drugs not included in the panel are done at the discretion of the Medical Examiner's Office. AXIS Forensic Toxicology, Inc. costs include the cost of the shipment to them and return and/or destruction of specimens. The type of services provided in the contract are exempt from the Purchasing Code. **Countywide (DC)**

Background and Policy Issues: Wuesthoff Reference Laboratory began toxicology specimen testing for the Palm Beach County Medical Examiner Office on June 1, 2001, ending June 30, 2017. Due to rising costs for their testing and excessively long turnaround times, the contract with Wuesthoff was not renewed. Medical Examiner cases continue to increase annually due primarily from an opioid epidemic that began in 2015. The continued rise in drug-related deaths has caused significant increases in both the number and complexity of toxicology tests. AXIS provides complete and complex toxicology analysis with a turnaround time of 2 weeks. These services include the storage of toxicology specimens for two years, then the return of specimens from homicide cases and destruction of all other specimens that are over two years of age.

Attachments:

- A. Contract for AXIS Forensic Toxicology, Inc. (2)
- B. Toxicology Panels-Scope of Testing

Recommended by: <u>*Phill Bell*</u> Department Director 11/30/17 12-12-17 Approved by: Deputy County Administrator Date

II. FISCAL IMPACT ANALYSIS

A. Five Year Summary of Fiscal Impact:

Fiscal Years	2018	2019	2020	2021	2022
		•			
Capital					
Expenditures					
Operating Costs	243,751	325,000	325,000	81,249	
External					
Revenues					
Program					
Income(County)					
In-Kind					
Match(County					
NET FISCAL	243,751	325,000	325,000	81,249	
IMPACT					
#ADDITIONAL					
FTE					
POSITIONS					
(CUMULATIVE					

Is Item Included in Current Budget?	Yes	No
Does this item include the use of federal funds?	Yes	No

Budget Account No:

Fund	Agency	Organization	Object
0001	670	4100	3431

B. Recommended Sources of Funds/Summary of Fiscal Impact:

Costs will be covered by County ad valorem general funds, Medical Examiner budget.

C. Departmental Fiscal Review:

III. REVIEW COMMENTS:

A. OFMB Fiscal and/or Contract Dev. and Control Comments:

Ar ist **ÓFMB**

Contract Der. & Control (2/11), 7 12/11/17/12

B. Legal Sufficiency

Assistant County Att/orney

С. **Other Department Review**

Department Director

(THIS SUMMARY IS NOT TO BE USED AS A BASIS FOR PAYMENT

CONTRACT FOR PROFESSIONAL SERVICES

This Contract is made as of the 1st day of January, 2018, by and between Palm Beach County, a Political Subdivision of the State of Florida, by and through its Board of Commissioners, hereinafter referred to as the COUNTY, and AXIS FORENSIC TOXICOLOGY, INC., a corporation authorized to do business in the State of Florida, hereinafter referred to as the CONSULTANT, whose Federal I.D. is 81-2989240.

In consideration of the mutual promises contained herein, the COUNTY and the CONSULTANT agree as follows:

ARTICLE 1 - SERVICES

The CONSULTANT'S responsibility under this Contract is to provide professional/consultation services in the area of forensic toxicology testing, as more specifically set forth in the Scope of Work detailed in Exhibit "A".

The COUNTY'S representative/liaison during the performance of this Contract shall be Michael D. Bell, M.D., telephone no.561-688-4575.

The CONSULTANT'S representative/liaison during the performance of this Contract shall be Phil Roberts, telephone no. 317-715-0442.

ARTICLE 2 - SCHEDULE

The CONSULTANT shall commence services on January 1, 2018 and complete all services by December 30, 2020.

Items shall be delivered or completed in accordance with the detailed schedule set forth in Exhibit "A".

ARTICLE 3 - PAYMENTS TO CONSULTANT

A. The total amount to be paid by the COUNTY under this Contract for all services and materials shall not exceed a total contract amount of Nine Hundred Seventy-five Thousand Dollars and No Cents (\$975,000). The CONSULTANT shall notify the COUNTY's representative in writing when 90% of the "not to exceed amount" has been reached. The CONSULTANT will bill the COUNTY on a weekly basis, or as otherwise provided, at the amounts set forth in Exhibit "B" for services rendered toward the completion of the Scope of Work. Exhibit "B" prices are based on a three (3) year term to be implemented by the approval of this contract.

- B. Invoices received from the CONSULTANT pursuant to this Contract will be reviewed and approved by the COUNTY's representative within five (5) business days of receipt, to verify that services have been rendered in conformity with the Contract. The COUNTY will process all approved invoices for payment on a monthly basis by transmitting the approved invoices to the Finance Department on the last day of each month. Invoices will normally be paid within thirty (30) days following transmittal to the Finance Department. The CONSULTANT and COUNTY agree that a late payment for purposes of Florida Statute Section 218.74 ("The Prompt Payment Act"), is thirty (30) days beginning from the last day of the month in which the invoice(s) was transmitted to the COUNTY.
- C. Final Invoice: In order for both parties herein to close out the Contract upon its termination or expiration, the CONSULTANT will clearly state "final invoice" on the CONSULTANT'S final invoice to the COUNTY. This shall constitute CONSULTANT'S certification that all charges and costs have been invoiced to Palm Beach County and the Contract can be closed out.

ARTICLE 4 - TRUTH-IN-NEGOTIATION CERTIFICATE

Signature of this Contract by the CONSULTANT shall also act as the execution of a truth-in negotiation certificate certifying that the wage rates, over-head charges, and other costs used to determine the compensation provided for in this Contract are accurate, complete and current as of the date of the Contract and no higher than those charged the CONSULTANT'S most favored customer for the same or substantially similar service.

The said rates and costs shall be adjusted to exclude any significant sums should the COUNTY determine that the rates and costs were increased due to inaccurate, incomplete or noncurrent wage rates or due to inaccurate representations of fees paid to outside consultants. The COUNTY shall exercise its rights under this Article 4 within three (3) years following final payment.

ARTICLE 5 - TERMINATION

This Contract expires on December 30, 2020 or until otherwise terminated in accordance to the provisions of this article.

This Contract may be terminated by the CONSULTANT upon thirty (30) days' prior written notice to the COUNTY's representative in the event of substantial failure by the COUNTY to perform in accordance with the terms of this Contract through no fault of the CONSULTANT. It may also be terminated, in whole or in part, by the COUNTY, with or without cause, upon thirty (30) days prior written notice to the CONSULTANT. Unless the CONSULTANT is in breach of this Contract, the CONSULTANT shall be paid for services rendered to the COUNTY'S satisfaction through the date of termination. Any unused supplies provided by CONSULTANT to COUNTY shall be returned to

CONSULTANT upon termination. After receipt of a Termination Notice and except as otherwise directed by the COUNTY the CONSULTANT shall:

- A. Stop work on the date and to the extent specified.
- B. Terminate and settle all orders and subcontracts relating to the performance of the terminated work.
- C. Transfer all work in process, completed work, and other materials related to the terminated work to the COUNTY.
- D. Continue and complete all parts of the work that have not been terminated.

ARTICLE 6 - PERSONNEL

The CONSULTANT represents that it has, or will secure at its own expense, all necessary personnel required to perform the services under this Contract. Such personnel shall not be employees of or have any contractual relationship with the COUNTY.

All of the services required hereunder shall be performed by the CONSULTANT or under its supervision, and all personnel engaged in performing the services shall be fully qualified and, if required, authorized or permitted under state and local law to perform such services.

The CONSULTANT warrants that all services shall be performed by skilled and competent personnel to the highest professional standards in the field.

All of the CONSULTANT'S personnel (and all Subcontractors), while on County premises, will comply with all COUNTY requirements governing conduct, safety and security.

ARTICLE 7 - SUBCONTRACTING

CONSULTANT has the right to use subcontractors of its choosing provided that the subcontractor fully complies with all Contract obligations, adheres to all standards for testing personnel and performance of tests as approved by CONSULTANT and required pursuant to this Contract. CONSULTANT shall not assign or transfer this Contract to another entity and shall remain responsible for the performance of all Contract obligations.

If a subcontractor fails to perform or make progress, as required by this Contract, and it is necessary to replace the subcontractor to complete the work in a timely fashion, the CONSULTANT shall promptly do so.

ARTICLE 8 - FEDERAL AND STATE TAX

The COUNTY is exempt from payment of Florida State Sales and Use Taxes. The COUNTY will sign an exemption certificate submitted by the CONSULTANT. The CONSULTANT shall <u>not</u> be exempted from paying sales tax to its suppliers for materials used to fulfill contractual obligations with the COUNTY, nor is the CONSULTANT authorized to use the COUNTY'S Tax Exemption Number in securing such materials.

The CONSULTANT shall be responsible for payment of its own and its share of its employees' payroll, payroll taxes, and benefits with respect to this contract.

ARTICLE 9 - AVAILABILITY OF FUNDS

The COUNTY'S performance and obligation to pay under this contract for subsequent fiscal years are contingent upon annual appropriations for its purpose by the Board of County Commissioners. In the event COUNTY does not receive sufficient appropriations to continue the Contract, COUNTY shall promptly notify CONSULTANT and terminate the Contract pursuant to Article 5 as a termination for convenience.

<u>ARTICLE 10 - INSURANCE</u>

- A. CONSULTANT shall, at its sole expense, agree to maintain in full force and effect at all times during the life of this Contract, insurance coverages and limits (including endorsements), as described herein. CONSULTANT shall agree to provide the COUNTY with at least ten (10) day prior notice of any cancellation, non-renewal or material change to the insurance coverages. The requirements contained herein, as well as COUNTY'S review or acceptance of insurance maintained by CONSULTANT are not intended to and shall not in any manner limit or qualify the liabilities and obligations assumed by CONSULTANT under the contract.
- B. <u>Commercial General Liability</u> CONSULTANT shall maintain Commercial General Liability at a limit of liability not less than **\$500,000** Each Occurrence. Coverage shall not contain any endorsement excluding Contractual Liability or Cross Liability unless granted in writing by County's Risk Management Department. CONSULTANT shall provide this coverage on a primary basis.
- C. <u>Business Automobile Liability</u> CONSULTANT shall maintain Business Automobile Liability at a limit of liability not less than \$500,000 Each Accident for all owned, nonowned and hired automobiles. In the event CONSULTANT doesn't own any automobiles, the Business Auto Liability requirement shall be amended allowing CONSULTANT to agree to maintain only Hired & Non-Owned Auto Liability. This amended requirement may be satisfied by way of endorsement to the Commercial General Liability, or separate Business Auto coverage form. CONSULTANT shall provide this coverage on a primary basis.

- D. <u>Worker's Compensation Insurance & Employers Liability</u> CONSULTANT shall maintain Worker's Compensation & Employers Liability in accordance with Florida Statute Chapter 440. CONSULTANT shall provide this coverage on a primary basis.
- E. <u>Professional Liability</u> CONSULTANT shall maintain Professional Liability or equivalent Errors & Omissions Liability at a limit of liability not less than \$1,000,000 Each Claim. When a self-insured retention (SIR) or deductible exceeds \$10,000, COUNTY reserves the right, but not the obligation, to review and request a copy of CONSULTANT'S most recent annual report or audited financial statement. For policies written on a "Claims-Made" basis, CONSULTANT shall maintain a Retroactive Date prior to or equal to the effective date of this Contract. The Certificate of Insurance providing evidence of the purchase of this coverage shall clearly indicate whether coverage is provided on an "occurrence" or "claims - made" form. If coverage is provided on a "claims - made" form the Certificate of Insurance must also clearly indicate the "retroactive date" of coverage. In the event the policy is canceled, non-renewed, switched to an Occurrence Form, retroactive date advanced, or any other event triggering the right to purchase a Supplement Extended Reporting Period (SERP) during the life of this Contract, CONSULTANT shall purchase a SERP with a minimum reporting period not less than three (3) years. CONSULTANT shall provide this coverage on a primary basis.

<u>Additional Insured</u> CONSULTANT shall endorse the COUNTY as an Additional Insured with a CG 2026 Additional Insured - Designated Person or Organization endorsement, or its equivalent, to the Commercial General Liability policy. The Additional Insured endorsement shall read "Palm Beach County Board of County Commissioners, a Political Subdivision of the State of Florida, its Officers, Employees and Agents." CONSULTANT shall provide the Additional Insured endorsements coverage on a primary basis.

- F. <u>Waiver of Subrogation</u> CONSULTANT hereby waives any and all rights of Subrogation against the County, its officers, employees and agents for each required policy. When required by the insurer, or should a policy condition not permit an insured to enter into a pre-loss agreement to waive subrogation without an endorsement to the policy, then CONSULTANT shall agree to notify the insurer and request the policy be endorsed with a Waiver of Transfer of rights of Recovery Against Others, or its equivalent. This Waiver of Subrogation requirement shall not apply to any policy, which specifically prohibits such an endorsement, or which voids coverage should CONSULTANT enter into such an agreement on a pre-loss basis.
- G. <u>Certificate(s) of Insurance</u> Prior to execution of this Contract, CONSULTANT shall deliver to the COUNTY'S representative as identified below, a Certificate(s) of Insurance evidencing that all types and amounts of insurance coverages required by this Contract have been obtained and are in full force and effect. Such Certificate(s) of Insurance shall include a minimum ten (10) day endeavor to notify due to cancellation or non-renewal of coverage. The certificate of insurance shall be issued to:

Palm Beach County c/o Medical Examiner's Office 3126 Gun Club Road West Palm Beach, FL 33406

- H. <u>Umbrella or Excess Liability</u> If necessary, CONSULTANT may satisfy the minimum limits required above for Commercial General Liability, Business Auto Liability, and Employer's Liability coverage under Umbrella or Excess Liability. The Umbrella or Excess Liability shall have an Aggregate limit not less than the highest "Each Occurrence" limit for either Commercial General Liability, Business Auto Liability, or Employer's Liability. The COUNTY shall be specifically endorsed as an "<u>Additional Insured</u>" on the Umbrella or Excess Liability, unless the Certificate of Insurance notes the Umbrella or Excess Liability provides coverage on a "Follow-Form" basis.
- I. <u>**Right to Review</u>** COUNTY, by and through its Risk Management Department, in cooperation with the contracting/monitoring department, reserves the right to review, modify, reject or accept any required policies of insurance, including limits, coverages, or endorsements, herein from time to time throughout the term of this Contract. COUNTY reserves the right, but not the obligation, to review and reject any insurer providing coverage because of its poor financial condition or failure to operate legally.</u>

ARTICLE 11 - INDEMNIFICATION

CONSULTANT shall protect, defend, reimburse, indemnify and hold COUNTY, its agents, employees and elected officers harmless from and against all claims, liability, expense, loss, cost, damages or causes of action of every kind or character, including attorney's fees and costs, whether at trial or appellate levels or otherwise, arising during and as a result of their performance of the terms of this Contract or due to the acts or omissions of CONSULTANT.

ARTICLE 12 - SUCCESSORS AND ASSIGNS

The COUNTY and the CONSULTANT each binds itself and its partners, successors, executors, administrators and assigns to the other party and to the partners, successors, executors, administrators and assigns of such other party, in respect to all covenants of this Contract. Except as above, neither the COUNTY nor the CONSULTANT shall assign, sublet, convey or transfer its interest in this Contract without the prior written consent of the other.

ARTICLE 13 - REMEDIES

This Contract shall be governed by the laws of the State of Florida. Any legal action necessary to enforce the Contract will be held in a court of competent jurisdiction located in Palm Beach County, Florida. No remedy herein conferred upon any party is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity, by statute or otherwise. No single or

partial exercise by any party of any right, power, or remedy hereunder shall preclude any other or further exercise thereof.

No provision of this Contract is intended to, or shall be construed to, create any third party beneficiary or to provide any rights to any person or entity not a party to this Contract, including but not limited to any citizen or employees of the COUNTY and/or CONSULTANT.

ARTICLE 14 - CONFLICT OF INTEREST

The CONSULTANT represents that it presently has no interest and shall acquire no interest, either direct or indirect, which would conflict in any manner with the performance of services required hereunder, as provided for in Chapter 112, Part III, Florida Statutes, and the Palm Beach County Code of Ethics. The CONSULTANT further represents that no person having any such conflict of interest shall be employed for said performance of services.

The CONSULTANT shall promptly notify the COUNTY's representative, in writing, by certified mail, of all potential conflicts of interest of any prospective business association, interest or other circumstance which may influence or appear to influence the CONSULTANT'S judgement or quality of services being provided hereunder. Such written notification shall identify the prospective business association, interest or circumstance, the nature of work that the CONSULTANT may undertake and request an opinion of the COUNTY as to whether the association, interest or circumstance would, in the opinion of the COUNTY, constitute a conflict of interest if entered into by the CONSULTANT. The COUNTY agrees to notify the CONSULTANT of its opinion by certified mail within thirty (30) days of receipt of notification by the CONSULTANT. If, in the opinion of the COUNTY, the prospective business association, interest or circumstance would not constitute a conflict of interest by the CONSULTANT, the COUNTY shall so state in the notification and the CONSULTANT shall, at its option, enter into said association, interest or circumstance and it shall be deemed not in conflict of interest with respect to services provided to the COUNTY by the CONSULTANT under the terms of this Contract.

ARTICLE 15 - EXCUSABLE DELAYS

The CONSULTANT shall not be considered in default by reason of any failure in performance if such failure arises out of causes reasonably beyond the control of the CONSULTANT or its subcontractors and without their fault or negligence. Such causes include, but are not limited to, acts of God, force majeure, natural or public health emergencies, labor disputes, freight embargoes, and abnormally severe and unusual weather conditions.

Upon the CONSULTANT'S request, the COUNTY shall consider the facts and extent of any failure to perform the work and, if the CONSULTANT'S failure to perform was without it or its subcontractors fault or negligence, the Contract Schedule and/or any other affected provision of this Contract shall be revised accordingly, subject to the COUNTY'S rights to change, terminate, or stop any or all of the work at any time.

ARTICLE 16 - ARREARS

The CONSULTANT shall not pledge the COUNTY'S credit or make it a guarantor of payment or surety for any contract, debt, obligation, judgement, lien, or any form of indebtedness. The CONSULTANT further warrants and represents that it has no obligation or indebtedness that would impair its ability to fulfill the terms of this Contract.

ARTICLE 17 - DISCLOSURE AND OWNERSHIP OF DOCUMENTS

The CONSULTANT shall deliver to the COUNTY's representative for approval and acceptance, and before being eligible for final payment of any amounts due, all documents and materials prepared by and for the COUNTY under this Contract.

To the extent allowed by Chapter 119, Florida Statutes, all written and oral information not in the public domain or not previously known, and all information and data obtained, developed, or supplied by the COUNTY or at its expense will be kept confidential by the CONSULTANT and will not be disclosed to any other party, directly or indirectly, without the COUNTY'S prior written consent unless required by a lawful court order. All drawings, maps, sketches, programs, data base, reports and other data developed, or purchased, under this Contract for or at the COUNTY'S expense shall be and remain the COUNTY'S property and may be reproduced and reused at the discretion of the COUNTY.

All covenants, agreements, representations and warranties made herein, or otherwise made in writing by any party pursuant hereto, including but not limited to any representations made herein relating to disclosure or ownership of documents, shall survive the execution and delivery of this Contract and the consummation of the transactions contemplated hereby.

Notwithstanding any other provision in this Contract, all documents, records, reports and any other materials produced hereunder shall be subject to disclosure, inspection and audit, pursuant to the Palm Beach County Office of the Inspector General, Palm Beach County Code, Sections 2-421 - 2-440, as amended.

ARTICLE 18 - INDEPENDENT CONTRACTOR RELATIONSHIP

The CONSULTANT is, and shall be, in the performance of all work services and activities under this Contract, an Independent Contractor, and not an employee, agent, or servant of the COUNTY. All persons engaged in any of the work or services performed pursuant to this Contract shall at all times, and in all places, be subject to the CONSULTANT'S sole direction, supervision, and control. The CONSULTANT shall exercise control over the means and manner in which it and its employees perform the work, and in all respects the CONSULTANT'S relationship and the relationship of its employees to the COUNTY shall be that of an Independent Contractor and not as employees or agents of the COUNTY. The CONSULTANT does not have the power or authority to bind the COUNTY in any promise, agreement or representation. Nothing herein shall be construed to create a joint venture or partnership between the parties hereto.

ARTICLE 19 - CONTINGENT FEES

The CONSULTANT warrants that it has not employed or retained any company or person, other than a bona fide employee working solely for the CONSULTANT to solicit or secure this Contract and that it has not paid or agreed to pay any person, company, corporation, individual, or firm, other than a bona fide employee working solely for the CONSULTANT, any fee, commission, percentage, gift, or any other consideration contingent upon or resulting from the award or making of this Contract.

ARTICLE 20 - ACCESS AND AUDITS

The CONSULTANT shall maintain adequate records to justify all charges, expenses, and costs incurred in estimating and performing the work for at least three (3) years after completion or termination of this Contract. The COUNTY shall have access to such books, records, and documents as required in this section for the purpose of inspection or audit during normal business hours, at the CONSULTANT'S place of business.

Palm Beach County has established the Office of the Inspector General in Palm Beach County Code, Section 2-421 - 2-440, as may be amended. The Inspector General's authority includes but is not limited to the power to review past, present and proposed County contracts, transactions, accounts and records, to require the production of records, and to audit, investigate, monitor, and inspect the activities of the CONSULTANT, its officers, agents, employees, and lobbyists in order to ensure compliance with contract requirements and detect corruption and fraud.

Failure to cooperate with the Inspector General or interfering with or impeding any investigation shall be in violation of Palm Beach County Code, Section 2-421 - 2-440, and punished pursuant to Section 125.69, Florida Statutes, in the same manner as a second degree misdemeanor.

ARTICLE 21 - NONDISCRIMINATION

The CONSULTANT warrants and represents that all of its employees are treated equally during employment without regard to race, color, religion, disability, sex, age, national origin, ancestry, marital status, familial status, sexual orientation, gender identity and expression, or genetic information.

CONSULTANT has submitted to COUNTY a copy of its non-discrimination policy which is consistent with the above paragraph, as contained in Resolution R-2014-1421, as amended, or in the alternative, if the CONSULTANT does not have a written non-discrimination policy, it has acknowledged through a signed statement provided to COUNTY that CONSULTANT will conform to the COUNTY's non-discrimination policy as provided in R-2014-1421, as amended.

ARTICLE 22 - AUTHORITY TO PRACTICE

The CONSULTANT hereby represents and warrants that it has and will continue to maintain all licenses and approvals required to conduct its business, and that it will at all times conduct its business activities in a reputable manner. Proof of such licenses and approvals shall be submitted to the COUNTY's representative upon request.

ARTICLE 23 - SEVERABILITY

If any term or provision of this Contract, or the application thereof to any person or circumstances shall, to any extent, be held invalid or unenforceable, the remainder of this Contract, or the application of such terms or provision, to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected, and every other term and provision of this Contract shall be deemed valid and enforceable to the extent permitted by law.

ARTICLE 24 - PUBLIC ENTITY CRIMES

As provided in F.S. 287.132-133, by entering into this contract or performing any work in furtherance hereof, the CONSULTANT certifies that it, its affiliates, suppliers, subcontractors and consultants who will perform hereunder, have not been placed on the convicted vendor list maintained by the State of Florida Department of Management Services within the 36 months immediately preceding the date hereof. This notice is required by F.S. 287.133(3)(a).

ARTICLE 25 - MODIFICATIONS OF WORK

Neither party shall make any changes without the signed written consent of the other and the execution of a formal Contract amendment. However, the parties acknowledge that CONSULTANT is in process of making changes to the emergent fentanyl analogs panel and the novel psychoactive substances panel (Currently Psychoactive Substances Panel (13610)). Therefore, CONSULTANT may present the revised emergent fentanyl analogs panel and the novel psychoactive substances panel to the COUNTY with revised pricing by sending the new panel descriptions and pricing to the COUNTY's Medical Examiner and the County's Medical Examiner may negotiate or consent to the revisions and if agreement is reached regarding the tests, such agreement shall be memorialized by execution of a written Contract addendum. In no event shall the cost to the COUNTY for the revised panels described herein exceed the cost to CONSULTANT's most favored customers. In the event the parties cannot agree on the revisions, either party may terminate the contract with sixty (60) days prior written notice to the other party and both parties shall be released from all further obligations.



<u>ARTICLE 26 – NOTICE</u>

All notices required in this Contract shall be sent by certified mail, return receipt requested, hand delivery or other delivery service requiring signed acceptance. If sent to the COUNTY, notices shall be addressed to:

Palm Beach County Michael D. Bell, M.D. Medical Examiner's Office 3126 Gun Club Road West Palm Beach, FL 33406

With a copy to:

Palm Beach County Attorney's Office 301 North Olive Ave. , 6th Fl West Palm Beach, Florida 33401

If sent to the CONSULTANT, notices shall be addressed to:

Axis Forensic Toxicology, Inc. P.O. Box 681513 Indianapolis, IN 46268

ARTICLE 27 - ENTIRETY OF CONTRACTUAL AGREEMENT

The COUNTY and the CONSULTANT agree that this Contract sets forth the entire agreement between the parties, and that there are no promises or understandings other than those stated herein. None of the provisions, terms and conditions contained in this Contract may be added to, modified, superseded or otherwise altered, except by written instrument executed by the parties hereto in accordance with Article 25- Modifications of Work.

ARTICLE 28 - CRIMINAL HISTORY RECORDS CHECK

If CONSULTANT'S employees or subcontractors are required under this contract to enter a "critical facility," as identified in Resolution R-2003-1274, the CONSULTANT shall comply with the provisions of Chapter 2, Article IX of the Palm Beach County Code ("Criminal History Records Check" section). The CONSULTANT acknowledges and agrees that all employees and subcontractors who are to enter a "critical facility" will be subject to a fingerprint based criminal history records check. Although COUNTY agrees to pay for all applicable FDLE/FBI fees required for criminal history record checks, the CONSULTANT shall be solely responsible for the financial, schedule, and staffing implications associated in complying with this section of the Palm Beach County Code.

ARTICLE 29 - REGULATIONS; LICENSING REQUIREMENTS

The CONSULTANT shall comply with all laws, ordinances and regulations applicable to the services contemplated herein, to include those applicable to conflict of interest and collusion. CONSULTANT is presumed to be familiar with all federal, state and local laws, ordinances, codes and regulations that may in any way affect the services offered.

ARTICLE 30 - SCRUTINIZED COMPANIES (when contract value is greater than \$1 million)

As provided in F.S. 287.135, by entering into this Contract or performing any work in furtherance hereof, the CONSULTANT certifies that it, its affiliates, suppliers, subcontractors and consultants who will perform hereunder, have not been placed on the Scrutinized Companies With Activities in Sudan List or Scrutinized Companies With Activities in The Iran Petroleum Energy Sector List created pursuant to F.S. 215.473, or on the Scrutinized Companies that boycott Israel List, or is engaged in a boycott of Israel, pursuant to F.S. 215.4725, or is engaged in business operations in Cuba or Syria.

If the County determines, using credible information available to the public, that a false certification has been submitted by CONSULTANT, this Contract may be terminated and a civil penalty equal to the greater of \$2 million or twice the amount of this Contract shall be imposed, pursuant to F.S. 287.135.

<u>ARTICLE 31 - PUBLIC RECORDS</u>

Notwithstanding anything contained herein, as provided under Section 119.0701, F.S., if the Consultant: (i) provides a service; and (ii) acts on behalf of the County as provided under Section 119.011(2) F.S., the Consultant shall comply with the requirements of Section 119.0701, Florida Statutes, as it may be amended from time to time. The Consultant is specifically required to:

- A. Keep and maintain public records required by the County to perform services as provided under this Contract.
- B. Upon request from the County's Custodian of Public Records, provide the County with a copy of the requested records or allow the records to be inspected or copied within a reasonable time at a cost that does not exceed the cost provided in Chapter 119 or as otherwise provided by law. The Consultant further agrees that all fees, charges and expenses shall be determined in accordance with Palm Beach County PPM CW-F-002, Fees Associated with Public Records Requests, as it may be amended or replaced from time to time.
- C. Ensure that public records that are exempt, or confidential and exempt from public records disclosure requirements are not disclosed except as authorized by law for the duration of the contract term and following completion of the Contract, if the Consultant does not transfer the records to the public agency.

D. Upon completion of the Contract the Consultant shall transfer, at no cost to the County, all public records in possession of the Consultant unless notified by County's representative/liaison, on behalf of the County's Custodian of Public Records, to keep and maintain public records required by the County to perform the service. If the Consultant transfers all public records to the County upon completion of the Contract, the Consultant shall destroy any duplicate public records that are exempt, or confidential and exempt from public records disclosure requirements. If the Consultant keeps and maintains public records upon completion of the Consultant shall meet all applicable requirements for retaining public records. All records stored electronically by the Consultant must be provided to County, upon request of the County's Custodian of Public Records, in a format that is compatible with the information technology systems of County, at no cost to County.

Failure of the Consultant to comply with the requirements of this article shall be a material breach of this Contract. County shall have the right to exercise any and all remedies available to it, including but not limited to, the right to terminate for cause. Consultant acknowledges that it has familiarized itself with the requirements of Chapter 119, F.S., and other requirements of state law applicable to public records not specifically set forth herein.

IF THE CONSULTANT HAS QUESTIONS REGARDING THE APPLICATION OF CHAPTER 119, FLORIDA STATUTES, TO THE CONSULTANT'S DUTY TO PROVIDE PUBLIC RECORDS RELATING TO THIS CONTRACT, PLEASE CONTACT THE CUSTODIAN OF PUBLIC RECORDS AT RECORDS REQUEST, PALM BEACH COUNTY PUBLIC AFFAIRS DEPARTMENT, 301 N. OLIVE AVENUE, WEST PALM BEACH, FL 33401, BY E-MAIL AT <u>RECORDSREQUEST@PBCGOV.ORG</u> OR BY TELEPHONE AT 561-355-6680.

ARTICLE 32 – DISCLAIMER OF WARRANTIES

CONSULTANT HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND WHETHER ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN STATEMENTS BY CONSULTANT OR OTHERWISE, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, TITLE AND ANY AND ALL WARRANTIES HEREINAFTER ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICE.

<u>ARTICLE 33 – COUNTERPARTS</u>

This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

IN WITNESS WHEREOF, the Board of County Commissioners of Palm Beach County, Florida has made and executed this Contract on behalf of the COUNTY and CONSULTANT has hereunto set its hand the day and year above written.

ATTEST: SHARON R. BOCK CLERK AND COMPTROLLER

By:__

Deputy Clerk

PALM BEACH COUNTY BOARD OF COUNTY COMMISSIONERS

AXIS FORENSIC TOXICOLOGY, INC. by

Mayor

PHILIP T. ROBERTS, CEO

By:_

By:

WITNESS:

usell and was Signature

Zenise Purdie Andr Name (type or print)

Philip T. Roberts, CEO Signature PTF

(corp. seal)

APPROVED AS TO FORM AND LEGAL SUFFICIENCY

By County Attorney

APPROVED AS TO TERMS AND CONDITIONS

mel By

Department Director

14

EXHIBIT "A" SCOPE OF WORK

CONSULTANT shall provide forensic toxicology services to COUNTY on an as-needed, fee-forservice basis as set forth in Exhibits "A" and "B". Various drug panels allow for screening, confirmation and quantitation of alcohols, carbon monoxide, and the drugs listed in Exhibit "A" in blood, urine, vitreous fluid, and other tissues from the submitted medical examiner case. CONSULTANT shall also detect glucose, urea nitrogen, creatinine, sodium, potassium and chloride in vitreous fluid. CONSULTANT shall invoice COUNTY on a weekly basis for completed services as required by Article 3 of this Contract. COUNTY shall process the invoices for payment on a monthly basis.

Testing results:

CONSULTANT shall provide COUNTY with 95% of the drug panel results within two weeks from the date of receipt of the complete order and specimen.

Records:

CONSULTANT shall provide the final toxicology report via fax or secure web portal subject to all applicable federal and state laws, rules and regulations pertaining to public records and confidentiality of records. CONSULTANT' toxicologists will be available to COUNTY for consultation and review of test results at no charge.

Specimen pickup, delivery, storage and return:

CONSULTANT will provide to the COUNTY supply kits which include all of the specific containers and requisition forms necessary for specimen collection and shipping to ensure that a proper chain of custody is maintained at no charge. CONSULTANT shall provide FedEx shipping labels and containers for specimen overnight transport to CONSULTANT at no charge.

CONSULTANT shall store all specimens in a secure freezer for 12 months [F.A.C. 11G-2.004(3)(c)] at no charge. All specimens will be maintained in refrigerated temporary storage until final testing is completed. Specimens will be stored appropriately to ensure against loss, contamination or deleterious change.

CONSULTANT will follow legal chain-of-custody procedures which comply with the applicable State and federal laws as well as the current test practices in forensic toxicology, including American Board of Forensic Toxicology (ABFT), the College of American Pathologists (CAP) test practices, and the Society of Forensic Toxicologists (SOFT) recommendations. Testing will be conducted on appropriate instrumentation including HPLC, LC/MS/MS, GC/MS, and GC/FID.

Expert witness/testifying at trial:

CONSULTANT shall provide appropriate witnesses or expert witness to testify in trial or deposition in any medical examiner case when subpoenaed to do so.

Certifications:

CONSULTANT shall maintain certification by the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), and the American Board of Forensic Toxicology (ABFT).

The chief toxicologist of CONSULTANT shall hold a relevant doctoral degree from an accredited institution. The chief toxicologist shall be certified by the American Board of Forensic Toxicology (ABFT) or certified in toxicological chemistry by the American Board of Clinical Chemistry or an international equivalent.

Products

CONSULTANT may adjust product descriptions/specifications from time to time provided same does not impact the services provided under this Contract and does not result in additional cost for the services contracted for herein.


Order Code	Panel	Price	Unit
13610 *	Psychoactive Substances Panel	\$ 135.00	per specimen
13810	Designer Opioid Panel – 1st specimen per case	\$ 135.00	per specimen
13810	Designer Opioid Panel – 2nd specimen per case	\$ 100.00	per specimen
13810	Designer Opioid Panel – 3rd specimen per case	\$ 65.00	per specimen
20040	Qualitative Drug Identification	\$ 400.00	per specimen
32400	Electrolytes Panel	\$ 75.00	per specimen
42130	Synthetic Cannabinoid Panel	\$ 240.00	per specimen
44060	Carbon Monoxide, Blood	\$ 60.00	per specimen
49910	Storage Only/No Testing	\$50.00	per case
70510	Comprehensive Panel, Blood	\$ 210.00	per case
70510T	Comprehensive Panel, Tissue	\$ 285.00	per specimen
70530	Drugs of Abuse Panel, Blood	\$ 125.00	per case
70531	Drugs of Abuse Extended Panel, Blood	\$ 175.00	per case

Exhibit B: Price List for District 15 FL Medical Examiner's Office

* Psychoactive Substances Panel (13610) currently encompasses both the Designer Opioid Panel (13810) for testing emergent fentanyl analogs panel per specimen and the Psychoactive Substances Panel (13610) for testing novel psychoactive substances for \$135.00 per panel per specimen. Axis anticipates a change to the composition and pricing of panels for psychoactive substances and fentanyl analogs to occur in Q4 2017. Details of the change will be communicated in accordance with Article 25.



DESIGNER OPIOIDS PANEL



SMR359v1.0

Updated Designer Opioids Panei Key Features & Benefits

- Latest, most relevant emergent designer opioid analytes
- Quantitative blood results
- Lower limit of detection to ensure no missed results
- Improved reporting
- Guicker turnaround time

BECAUSE NOT ALL OPIATES ARE CREATED EQUAL ...

58% of samples tested with the Designer Opioids Panel were found positive for one or more analytes." Axis recommends ordering this panel for all fatalities that have circumstances consistent with Opioid use or intravenous drug abuse and negative routine blood tonicology for opiates/opioids such as 6-AcetyImorphine, morphine, and fentanyl. "Data Source: Axis analyzed 1,408 blood specimens for the presence of fentanyl analogs and designer opioid analytes using LC/MS/MS between July 2016 to July 2017.

ORDER CODE: 15810	
SAMPLE TYPE: Blood, Urine", Vitreous"	
MINIMUM SAMPLE VOLUME: 0.5 mL (2mL preferred)	· · · · · · · · · · · · · · · · · · ·
ANALYTES INCLUDED:	Reporting Limit:
4-Methoxybutyrylfentanyl	0.05 ng/mL
Acetylfentanyl	0.05 ng/mL
Acrylfentanył	0.05 ng/mL
Beta-hydroxythiofentanyl	0.10 ng/mL
Butyrylfentanyl	0.05 ng/mL
Carfentanil	10 pg/mL**
cis-3-Methylfentanyl	0.20 ng/mL
Cyclopropylfentanyl	0.05 ng/mL
Furanylfentanyl	0.05 ng/mL
Ocfentanil	0.05 ng/mL
Para-fluoroacrylfentanyl	0.05 ng/mL
Para-fluorobutyrylfentanyl/Para-fluoroisobutyrylfentanyl	0.05 ng/mL
Tetrahydrofuranfentanyl	0.05 ng/mL
U47700	0.10 ng/mL

*Urine and Vitreous results are reported qualitatively. **Carfentanil results reported qualitatively between 10-20 pg/mL.

小学》《《古》

Effective Date: 12/1/2017



0)|| S-ROUTINE ANALS 7SIS IN THE TOXICOLOGY

INTERESTED IN NON-ROUTINE OR ESOTERIC TESTING?

FOR OVER 25 YEARS, AXIS HAS PERFORMED NON-ROUTINE ANALYSES ON A MULTITUDE OF SUBSTANCES

MOR-ROUTINE TESTING MOLUDING:

- Suspected illicit drug substances
 Designer substances such as: including:
 - Methamphetamine
 - Cocaine.
 - Heroin
 - PCP
- Syringes
- Residues

- Synthetic Cannabinoids • Hallucinogens
- Cathinones
- Opioids/Fentanyl Analogs
- Tablets/Pills/Capsules
- Liquids

WED CAM BENEFIT FROM NON-NOUTINE TESTINGS

- Attorneys
- Medical Examiners/Coroners
- Law Enforcement Officials or Agencies
 Drug Chemistry Labs
- Emergency Rooms • Poison Centers

OM I INQUIRIES@AXISFORTOX.CC


SERVICES

- Qualitative Drug Identification
- Order code: 20040
- Quantitative Drug Analysis
- Order code: 20000
- Special Method Development
- Order code: 20020

For pricing, please contact Inquiries at 317-715-0448 (opt. 6) or via email at inquiries@axisfortox.com.

RTOX

SMR353_v1.0



Effective Date: 2/16/2017



HEROIN AND EMERGENT FENTANYL ANALOGS: PARTNERING WITH AXIS FORENSIC TOXICOLOGY

Axis Forensic Toxicology offers testing for emergent fentanyl analogs and opioid research chemicals as a special request add-on to our New Psychoactive Substances panel, order code 13610.

The scope of this add-on testing currently includes:

MAME	MATREC	Mimirium Specimem Volume	REPORTING LIMIT	METHOD
3-methylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
4-methoxybutyrylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Acrylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Acetylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Beta-hydroxythiofentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Butyrylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Carfentanil	Blood, Urine*	0.5 mL	10 pg/mL	LC/MS/MS
Furanylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
Para-fluorobutyrylfentanyl	Blood, Urine*	0.5 mL	0.2 ng/mL	LC/MS/MS
U47700	Blood, Urine*	0.5 mL	2 ng/mL	LC/MS/MS

* Urine results are reported qualitatively.

To order this testing, please select order code 13610 and notate on the Axis Forensic Toxicology specimen requisition that you would like to test for fentanyl analogs/opioids. If a specific drug, such as Furanylfentanyl or Carfentanil, is being targeted, please also notate.

Please note: Whenever feasible, paired blood and urine specimens from a decedent or living subject are preferred. We also ask that you include as much case history and information as possible.

For more information about the other services and panels AXIS provides, please contact us at sales@axisfortox.com. SMR359v2.0

317-759-4TOX | AXISFORTOX.COM | SALES@AXISFORTOX.COM



NOVEL PSYCHOLONINE SPESTICLES PANEL

Panel updated to include a wide variety of substances that have emerged in the illicit drug market:

- Depressants
- Hallucinogens
- Dissociatives
- Stimulants

(Please see reverse side for the complete list of analytes included in panel.)

AXIS

Alternate Names	Bath Salts, Plant Food, Glass Cleaner, Jewelry Cleaner, Ivory Wave, Vanilla Sky, Molly, Flakka, Gravel, NBOME, Research Chemicals
Facts	 The Drug Enforcement Agency (DEA) recognizes newly emerging psychoactive substances as serious public health threats¹
	• Illicit similar effects as methamphetamine, cocaine, MDMA, LSD, opioids or benzodiazepine
	 Can be smoked, snorted, orally ingested, bucally absorbed or injected
	• Sold in powder, crystal, tablet, or liquid form; can also be found on blotter paper
	 Adverse side effects include: hyperthermia, hypertension, nausea, vomiting, agitation, violent behavior, panic attacks, delusions, hallucinations, suicidal ideation, seizure and death¹

SMR295v1.0

Effective Date: 12/1/2017



SMR295v1.0

317-759-4 TOX 1 ANJSE

ORDER CODE: 13610 SAMPLE TYPE: Blood, Urine*, Vitreous* MMMUM SAMPLE VOLUME: 0.5 mL (Aml. preferred) ANALYTES INCLUDED: REPORTING LIMIT: 25B-NBOMe 0.5 ng/mL 25C-NBOMe 0.5 ng/mL 251-NBOMe 0.5 ng/mL Alpha-PVP 5 ng/mL Butylone 5 ng/mL Clonazolam 5 ng/mL Dubutylone 5 ng/mL Dimethylone 5 ng/mL Ethylone 5 ng/mL Etizolam 5 ng/mL Flubromazolam 5 ng/mL MDPV 5 ng/mL Methoxetamine 5 ng/mL Methylone 5 ng/mL N-Ethylpentylone 5 ng/mL Pentylone 5 ng/mL

*Urine and Vitreous results are reported qualitatively.

Effective Date: 12/1/2017

Othir

लन्म उद्यु **INCREASING PREVALENCE OF SYNTHETIC** CANNABINOID COMPOUNDS

DRUGS ARE AL

$$\begin{split} & \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} = \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} = \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} = \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} = \mathcal{L}_{\mathrm{s}}^{\mathrm{c}} \mathcal{L}_{\mathrm{s}}^{\mathrm{c}}$$
26.1 $(r) \in [r(f(z))] \setminus \{r(z)^n\}$ 2010-2011 2012-2013 2014 2015-2018

AXIS FORENSIC TOXICOLOGY PANELS HELP **KEEP YOUR TESTING UP-TO-DATE**

PSYCHOACTIVE SUBSTANCES PANEL

Test Code:	13610
Specimen Type:	Whole Blood, Serum/Plasma, Urine
Sample Volume:	0.5 mL (minimum)
Method of Analysis:	Ultra Performance Liquid Chromatography - Tandem Mass Spectrometry (UPLC/MS/MS)
Analytes Included:	25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25H-NBOMe, 25I-NBOMe, Acetylfentanyl, Alpha-PBP, Alpha-PPP, Alpha-PVP, Buphedrone, Butylone, Etizolam, Ethylmethcathinone, Ethylone, Flephedrone, MDPV, Mephedrone, Methedrone, Methoxetamine, Methylethcathinone, Methylone, Pentedrone and Pentylone
Reporting Limits Vary:	0.5 ng/mL for Acetylfentanyl, 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25H-NBOMe, 25I-NBOMe; 2 ng/mL for Methoxetamine; 5 ng/mL for Alpha-PBP, Alpha-PPP, Alpha-PVP, Buphedrone, Butylone, Etizolam, Ethylmethcathinone, Ethylone, Flephedrone, MDPV, Mephedrone, Methedrone, Methylethcathinone, Methylone, Pentedrone and Pentylone

SYNTHETIC CANNABINOIDS PAHEL (K2/SPICE)

Blood Test Code:	42130
Specimen Type:	Whole Blood
Sample Volume:	2 mL (minimum)
Method of Analysis:	Ultra Performance Liquid Chromatography - Tandem Mass Spectrometry (UPLC/MS/MS)
Analytes included:	5F-AB-PINACA, 5F-ADB, 5F-ADB-PINACA, 5F-AMB, 5F-NNEI, 5F-PB-22, 5F-THJ, AB-CHMINACA, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, ADB-PINACA, AM-2201, AMB, APP-FUBINACA, BB-22, CI-2201, EAM-2201, FAB-144, FDU-PB-22, FUB-AMB, FUB-PB-22, JWH-015, JWH-018, JWH-019, JWH-073 JWH-081, JWH-122, JWH-210, JWH-250, M-144, MAB-CHMINACA, MA-CHMINACA, MAM-2201,
	MDMB-CHMICA, MDMB-CHMINACA, MDMB-FUBINACA, MN18, MO-CHMINACA, NNEI, PB-22, PX1, PX2, PX3, SDB-006, THJ, THJ-018, THJ-2201, UR-144, XLR11, XLR12

Reporting Limit:

0.2 ng/mL

For more information about the other services and panels AXIS

provides, please contact us at sales@axistortex.com.

SMR359v2.0



317-759-4TOX I AMISFORTOX.COM I SALES@AXISFORTOX.COM




FORENSIC ANALYTE PANELS

					OCTANI STATISTICS		
A CALL AND A CALL	C. M. S. C.	(Wanthhouse)				Arshina and	
		Comprehensive	Comprehensive Panel, Tissue(705107);		Drugsof	Drugs of Abuse,	Drugs of
	Analyte Name	Panel, Blood (70510)	Vitreous (70510V),	Extended Panel, Blood (70531)	Abuse, Blood	Tissue (70530T), Vitreous (70530V),	Abuse, Urine
			and Fluid (70510FL)		(70530)	and Fluid (70530FL)) .	(70080)
Alcohols	Acetone	X	x	X	X	X	
	Ethanol	X	X	X	X	X	Contraction of the
	Isopropanol	$\mathbf{x} = \mathbf{x}$	x	X	X	x	
and when the second second second as	Methanol	X	X	X	X	X	
Amphetamines	Amphetamine	x	X	X	x	X	X*
	BDB	x					
	Benzphetamine	X					
	Ephedrine	х	х	Х	х	x	
	MDA	x		X			
	MDMA	х	x	х	x	х	X*
	Mescaline	Х+		X*			
· ·	Methcathinone	Х	X				
	Methamphetamine	X	x	x	X	x	Х‡
	Phentermine	x		X			
	РМА	X	x	x			
	Phenylpropanolamine (PPA)	X	an an an an ann an Aonaichtean an A	X	Sharing and the State Street Special	<u>na na kaodimina dia kaodimina dia kaodim</u> ina dia kaodimina dia kaodimina dia kaodimina dia kaodimina dia kaodimina	A light faith an in the state
	Pseudoephedrine	X	x	X.	x x	x	
Analgesics	Acetaminophen	X	x x x x x x x x x x x x x x x x x x x	X	<u>, Calendra (Marine a Ma</u> ri	<u>n an 1977 - a de la Mindere e Anne, en en e</u>	
	Baclofen	X		x			
	Buprenorphine	x	X	x	X	X	X*
	Carisoprodol	ι 	x	x	x	x	
	Cyclobenzaprine	X	X	x	Eletyteligervirust		
	Diclofenac	X					
<u>general en la sector de la sector</u>	Etodolac	x			<u> All Interfer Frankliker</u> I	ne na secto na destructura e destructura de la secto de la sec	<u>. Nek alema a a l'ha a</u>
	Fenoprofen	X					and a state of the second s
	Hydroxychloroquine	X		X			
	Ibuprofen	X	x	x			
<u>erios antes de capes estr</u>	Ketoprofen	X				방법 방지 않는다. 지난 가격 가 있는다. 가 가	<u> 전체 일본 전체</u>
	Ketorolac	x					
	Meclofenamic Acid	х*					<u>en di Base Sel</u>
	Meprobamate	X	X	x	x	x	Xt
		ne oligi mender selar ser a terret a terret	na an a	ne meterier, store date in the state of the state		A	- A
	Metaxalone	X	X	X			
	Methocarbamol			X			
	Naloxone	X*		X*		eesse ta konstantii dheanaan eessa ah dhalka ta ta	

*Denotes screen-only analysis.

317-759-4TOX | AZISFORTOX.COM | SALES@AXISFORTOX.COM






TORENSIC TORICO		The second second second	Antalis of the large statement	and the state of the second	un anna fiailte	and shall be a second	and the second second
	Analyte Name	Comprehensive Panel,	Comprehensive Panel, Tissue (70510T), Vitreous (70510V),	Extended Panel,	Drugs of Abuse	Drugs of Abuse Tissue (70530T) Vitreous (70530V)	Drugs of Abuse,
		Blood (70510)	and Fluid (70510V), and Fluid (70510FL)	Blood (70531).	Blood (70530)	Vitreous (70530V), and Fluid (70530FL)	Urine . (70080)
	Naproxen	X	X	x			
	Norbuprenorphine	x	x	x	x	x	X*
	Nortramadol	X	x	X	x	X	
	o-Desmethyltramadol						X*
	Oxaprozin	X		x			
	Pentoxifylline	X		X			
	Phenacetin	X					
	Phenylbutazone	x				1 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	
	Piroxicam	x					
	Salicyclic Acid	X*	X*	X*	1327		
	Sulindac	X					
	Tapentadol	x	х	X			
	Tizanidine	x		X			
	Tolmetin	x					
	Tramadol	Χ	- X	X	X	x	X*
Anesthetics	Benzocaine	X					
	Bupivacaine	X	x	x			
	Etomidate	X	x	х			
	Ketamine	X	x	X			
	Lidocaine	X	X	x			
	Mepivacaine	x					
	Methoxetamine	X	х	x			
	Midazolam	x	x	-x-			
	Norketamine	X		x			
	Prantoxine	X *		40 at			
	Procaine	X	line de la construction de la const				
	Rocuronium	X	x	x			
	Ropivacaine	X					
Antibiotics	Azithromycin	X*		() - Sei sei			
	Chloramphenicol	X*		a a concentre d'Arcanacia	n Na kana tanin da awa ka wa		
	Ciprofloxacin	X*					
an a	Clindamycin	X*		e de state de la compansióne de la comp	-Al-Adamster and descent		10 A WAR
	Erythrömýcin	X*			Mendela		
	Levofloxacin	X*	stanti i sanatang sanatan katang sanatan sa	an a	The second states and a second	1. Ale 1994 - Clark and the book of the second	
	Tilmicosin 10-	X					
Anticonvulsants	10- monohydroxyoxcarbazepine	Х	Х	Х			

*Denotes screen-only analysis.

Page 2 of 8





Effective Date: 10/15/2017

FORENSIC TOXICO							1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
		Friday and a start start of the	Comprehensive Panel,		Drugs of	Drugs of Abuse,	Drugs of
	Analyte Name	Comprehensive Panel, Blood (70510)	Tissue (70510T); Vitreous (70510V); and Fluid (70510FL)	Extended Panel, Blood (70531)	Abuse, Blood	Drugs of Abuse, Tissue (70530T), Vitreous (70530V), and Fluid (70530FL)	Abuse,
以非管理对是影响		Biood (70510)	and Fluid (70510FL)		(70530)	and Fluid (70530FL)	(70080)
		and the state of the					1999 (1999) 1999 (1999) 1999 (1999)
	Carbamazepine	x	x	X			
	Carbamazepine-10,11- epoxide	x	x	X	a Posta Nejvična – 15		<u> </u>
	Felbamate	X	x	X			
a na sana ang ang ang ang ang ang ang ang ang	Gabapentin	x	X	x			
	Lamotrigine	X	x	X			
	Levetiracetam	Х	x	X			
	Methsuximide	x					
	Phenytoin	x	x	x			
	Pregabalin	x	x	x			
	Primidone	x	x	x			
	Topiramate	x	x	x			
	Zonisamide	х	х	x			
Antidepressants	Amitriptyline	X	X	x			
	Amoxapine	x		x			
	Bupropion	X	x	X			
	Citalopram	х	х	x			
	Clomipramine	x	$\mathbf{x}_{\mathbf{x}}$	x			
	Desipramine	х	Х	x			
	Desmethylclomipramine	X					
	Dosulepin	x					
	Doxepin	x	X	x			
	Duloxetine	х	х	х			
	Fluoxetine	X	x	x			
	Fluvoxamine	X		x			
	Imipramine	- x	x	- X			
ana mananan mananin kata mananan da katak	1,3-chlorophenylpiperazine (mCPP)	Х	X	Х			
	Mianserin	X*					
	Mirtazapine	X	X	x			<u></u>
	Nefazodone	x					
	Norclomipramine	X	X	X		n - Chanada Antonio Indonesia di Antonio di A	
	Nordozepin	¥	x	X			
an an than the statistic for the statistic	Norfluoxetine	x	x	X			<u>nan sinensa</u>
	Norsertraline	x	x	X			
	Nortriptyline	x	X	x	ne served der Frieder.		<u></u>
	Norvenlafaxine	X	X	x			
	Paroxetine	x	x	x		<u>an an an thù thài an thair 1868. An 1868</u> -	

*Denotes screen-only analysis.

Page 3 of 8

For reference only. Please visit the Test Catalog at axisfortox.com for the most current panel information.

Effective Date: 10/15/2017



							der i
	Analyte Name	Comprehensive Panel,	Comprehensive Panel, Tissue (70510T),	Extended Panel,	Drugs of Abuse,	Drugs of Abuse, Tissue (70530T),	Drugs of Abuse,
	Allelycenance	Blood (70510)	Vitreous (70510V). and Fluid (70510FL)	Blood (70531)	Blood (70530)	Vitreous (70530V), and Fluid (70530FL)	Urine (70080)
自己的影响。							
	Protriptyline	X					
	Sertraline	X	X	x			
	Trazodone	x	x	X	d provinsi - en	مى ئەرىپى ئەتلەر ئە ئەتلەر ئەتلەر	
	Trimipramine	x	x	x			
	Venlafaxine	X	x	x			
Antihistamines	Brompheniramine	x		x			
	Cetirizine	X	X	X			h de la charte de la composition de la Composition de la composition de la comp
	Chlorpheniramine	x	x	X			
	Cyclizine	X					
	Diphenhydramine	x	x	X	an and a construction		
	Doxylamine	x	x	- X - 1			
	Fexofenadine	x	x	X	a na seu como como como e se		
	Guaifenesin	x		X .			
n an start an	Hydroxyzine	X		X			
	Loratadine	X		x			
	Oxymetazoline	X*					
	Pyrilamine	x		X			
and the second	Tetrahydrozoline	X		X	and the state of the state of the state		
	Triprolidine	X					
Antipsychotics	9-Hydroxyrisperidone	X		X	en e		8 - 1
	Aripiprazole	X		X			
	Buspirone	X		X			
n - P	Chlorpromazine	X		X			
	Clozapine	X	X	X	rational and a state of the second		
	Fluphenazine	$= \sum_{i=1}^{n} \left(\frac{1}{2} \sum_{i=1}^{n} \sum_{j=1}^{n} \sum_{$			n an		
	Haloperidol	X	X	X			<u></u>
	Mesoridazine	X		X			
	Norclozapine	X	X	X			國國共和國
	Olanzapine	X	x	x			
	Perphenazine	X			Alternation (Marchael) (Marchae		aser a
	Pimozide						
	Prochlorperazine	X X		x	· · · · · · · · · · · · · · · · · · ·		
	Quetiapine	and the second	×				
	Risperidone	X		x 			an said
	Thioridazine	X. (1)		X			
	Trifluoperazine	Х					

*Denotes screen-only analysis.

Page 4 of 8



Effective Date: 10/15/2017

FORENSIC TOXICC	DLOGY	enter Many a Cardin Sa	Linder Witte Statistics		n a Billion and		al Zale Sa
		Comprehensive	Comprehensive Panel,		Drugs of	Drugs of Abuse,	Drugs of
	Analyte Name	Panel, Blood (70510)	Tissue (70510T), Vitreous (70510V), and Fluid (70510FL)	Extended Panel, Blood (70531)	Abuse, Blood (70530)	Tissue (70530T), Vitreous (70530V), and Fluid (70530FL)	Abuse, Urine (70080)*
	Ziprasidone	X		x			
Barbiturates	Amobarbital	X	X	X	X	X	x
	Butabarbital	x	x	x	x	x	x
	Butalbital	X	X	X	X	X	X
	Pentobarbital	x	X	X	x	x	x
	Phenobarbital	x	x	x	X	x	x
	Secobarbital	x	x	X	x	x	x
Bath Salts	Alpha-PVP	x		Х	x		
	MDP⊽	x		x	X		
	Mephedrone	x		x	x		
	Methylone	x		X	×		
Benzodiazepines	2-hydroxyethylflurazepam	x					
	7-aminoclonazepam	x	x	x	X	x	X*
	Alprazolam	x	х	x	x	х	X*
	Alphahydroxyalprazolam			د میتونی ایر دوروند. دستونی (ایر منبع			X*
····	Bromazepam	X*		X*			
	Chlordiazepoxide	x	x	x	x	x	
	Clonazepam	X	X	x	x	Х	
	Demoxepan	X	x	Х.			
	Desalkylflurazepam	X		х			
	Diazēpan:	x	x	x	x	x	
	Estazolam	X		X			
	Flumazenil	X*					
	Flurazepam	X		X			
	- Hydroxytriazolam	x					
uranes spinsor anne metadore	Lorazepam	X	X	X	X	X	X*
	Lormetazepam						
	Medazepam	X*		r mana an an ann an an an an an an an an an			
	Nitrazepam	X		X			
	Nordiazepam	X	X	X	X	X	X*
	Oxazepani	X	X	X	X	×	X*
	Phenazepam	X		X	<u>25046288</u> 04		
	Temazepam	X	X	X	X	x	X*
	Tetrazepam	X*					
	Triazolam	X		X			
Cannabinoids	ТНС	Х	Х	X	Х	Х	

*Denotes screen-only analysis.

Page 5 of 8



Effective Date: 10/15/2017

FORENSIC TOXICO		en den de sterre	EFST WAR PHONE MARK &		i kili jest (j		
		Comprehensive	Comprehensive Panel; Tissue (70510T); Vitreous (70510V);	Ettended Panel	Drugs of Abuse;	Drugs of Abuse, Tissue (70530T), Vitreons (70530V),	Drugs of Abuse,
	Analyte Name	Panel, Blood (70510)	Vitreous (70510F), and Fluid (70510FL)	Extended Panel, Blood (70531)	Blood (70530)	Vitreous (705301), and Fluid (70530FL)	(70030)
	a transformer de la constant						
	ТНС-СООН	x	X	X ·····	x	X	X
Cardiovascular	Acebutolol	x	<u>Anther COMPUTED in a set official states in a set of the set of t</u>	<u>n an an</u>	<u> 28. (1793), 19. (</u>		
	Alprenolol	X*					
	Amiodarone	X*		X*			
	Amlodipine	x	X	X			
	Atenolol	x	X	x			
	Betaxolol	*		X*			
	Bisoprolol	x		X			
	Butaxaniine	X*					
	Chlorothiazide	x					
	Coumarin	Χ*					
	Diltiazem	x		Х			
	Disopyramide	×					
	Esmolol	X*					
	Flecainide			X			
	Furosemide	x		X			
	Hydrochlorothiazide	X.		X			
	Labetalol	. X		X			
	Metoprolol	x	x	x			
	Mexiletine	X	x	- the second state of the second state of the	the second second second second		
	Nadolol	$\mathbf{x}_{i} = \mathbf{x}_{i-1} \cdot \mathbf{x}_{i-1}$		$= \frac{1}{2} \sum_{i=1}^{n-1} \frac{1}{2} \sum_{i=1}^{n$	和知識		
	Nifedipine	X		Na manana mangana mangana	Contract Vision, process (2017)	CHER STREET, STREET, STREET, ST	
	Oxprenolol	- X 4					
	Papaverine	X	a sana sa dana masa sa ang sanara sa sa sa sa	x		a na sana kana sa marakan jara kati si kati sa sa sa sa	
	Pindolol	X					
	Procainamide	X					1112-09-07-0
	Propranolol	×	×	X			
	Quinidine	X	ana ang sang ang sang ang sang sang sang		Persente de la company		And the first of the
	Reserpine	X					<u> Gerope</u>
	Sotalol	X		X			1. Selection and the
	Timolól	X					
	Triamterene	X					
	Verapamil	X	X	x			Market State
	Warfarin	X	X	X			1 - Charles - Ch
Cocaine/Metabolites	Benzoylecgonine		x		- X	x	
il	Cocaethylene	х	X	X	X	Х	

*Denotes screen-only analysis.

Page 6 of 8

For reference only. Please visit the Test Catalog at axisfortox.com for the most current panel information.

Effective Date: 10/15/2017



FOREMSIC TOXICC	LOGY	li alla sta na	A THE R ALL AND THE STREET AND	in the second second	and the state of the second	a surffaire de sur au au au	and falls are first
	AnalyteName	Comprehensive Panel,	Comprehensive Panel, Tissue (70510T);	Extended Panel,	Drugs of Abuse,	Drugs of Abuse, Tissue (70530T), Vitreous (70530V),	Drugs of Abuse,
		Blood (70510)	Vitreous (70510V), and Fluid (70510FL)	Blood (70531)	Blood (70530)	Vitreous (70530V). and Fluid (70530FL)	Urine (70080)
·····································							
	Cocaine	X	X	X	X	X	and For Statistics of Section
Endocrine	Betamethasone	X*			n ter ter son in ter blander.	<u>n 18 kina (h. 1817). Este a Charactean</u>	
	Chlorpropamide	x					
<u></u>	Dexamethasone	X*		a little of the state of the st			
	Probenecid	X*					
	Tolbutamide	x					
Fentanyl	Acetylfentanyl	x	X	X			
	Fentanyl	х	x	x	x	x	X*
	Norfentanyl						X*
Gastrointestinal	Emetine	x					
	Metoclopramide	x		x			
	Ranitidine	х		х			
GHB	GHB (Gamma- hydroxybutyrate)						
Methadone	EDDP	x	х	х	x	x	X*
	EMDP (only reported if Methadone/EDDP present)						
	Methadone	х	x	x	х	х	X*
Narcotics	Alfentanil	x	x	X =			
	Butorphanol	х					
	Dextromethorphan	X	X	x			
	Meperidine	х	x	х			
	Naltrexone	x				ana ang pang pang pang pang pang pang pa	
	Normeperidine	Х	Х	х			
	Pentazocine	X	x	.X., 7.			
	Sufentanil	X		Х			
Neurologicals	Benztropine	x		x			
	Donepezil	X		x			
	Ropinirole	X		X			
	Sumatriptan	Х		x			
	Trihexyphenidyl	X		x			
Opiates	6-MAM	X	X	X	X	X	X*
	Codeine	X	X	X	X	X	Х*
1	Desomorphine	Х	X	X			
	Dihydrocodeine	x		X			
	Hydrocodone	X	X	X	X	X	X*
	Hydromorphone	x	×	x	X	X	X *
	Morphine	х	Х	x	Х	Х	Х*

*Denotes screen-only analysis.

Page 7 of 8

For reference only. Please visit the Test Catalog at axisfortox.com for the most current panel information.

Effective Date: 10/15/2017



FORENSIC TOXICO		walter and the forest of the second second	Marks has a series of a series of a	and the stand of the second	the state of the second se	in a statistic to a statistic for	2 of Standar 18
						的复数形式推动	
	Analyte Name	Comprehensive Panel,	Comprehensive Panel, Tissue (70510T), Vitreous (70510V),	Extended Panel.	Drugs of Abuse,	Drugs of Abuse, Tissue (70530T), Vitreous (70530V),	Drugs of Abuse,
	Analyce value	Blood (70510)	Vitreous (70510V), and Fluid (70510FL)	Blood ((70531)	Blood (70530)	 Vitreous (70530V), 4 and Fluid (70530FL) 	Urine (70080)
				T. A. Y. A.			
La caracteria de la Manda de la caracteria	Nalorphine (only reported if Opiates present)	X‡					
	Noscapine (only reported if Opiates present)	X*			<u> </u>	<u>e al 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 </u>	
	Oxycodone	X	X	X	x	X	X ⁴
<u>n en en el trens de la constante a forma señel definitado</u>	Oxymorphone	X	X	x	x	X	X*
	Pholcodine	X*					
	Thebaine	x					
Phencyclidine	Phencyclidine (PCP)	x	X	X	x	x	X*
Propoxyphene	Norpropoxyphene	x	x	х	х	х	
	Propoxyphene	x	x		x	x	
Sedatives/Hypnotics	7-aminoflunitrazepam	x	х	x			
	Desmethylflunitrazepam	x					
	Flunitrazepam	x	x	x			
	Glutethimide	x					
	Methaqualone	x		x			
	Orphenadrine	×	x	X			
	Promethazine	х	x	x			
	Ramelteon	X		x			$ \begin{array}{c} x_{1}^{2} & z_{1}^{2} \\ x_{2}^{2} & z_{1}^{2} \\ z_{1}^{2} & z_{2}^{2} \\ z_{1}^{2} & z_{1}^{2} \\ z_{2}^{2} & z_{1}^{2} \\ z_{1}^{2} & z_{2}^{2} \\ z_{1}^{2} & z_{1}^{2} \\ z_{2}^{2} & z_{1}^{2} \\ z_{1}^{2} & z_{1}^{2} $
	Zaleplon	x		x			
	Zolpidem	x	X	x			
	Zopiclone	х		x			
Stimulants	Atomoxetine	x		X	anan ana ang ang ang ang ang ang ang ang		
	Benzylpiperazine (BZP)	X*		X*	a wa wa kwa wakazia		
	Caffeine	×*	X*	X*			
	Cotinine	X*	X*	X*	8		
	Methylphenidate	X	x	×	S. 44. (* 1		
	Nicotine	Х*	X*	X*	rina anto Pontanto a parteta da		and the second second second
	Strychnine	X	x	x			
	1,3- trifluoromethylphenylpipera zine (TFMPP)	X*		X*			
Urologicals	Sildenafil	x +		X			
	Tadalafil	X	e na sene de la calegra del specie por este della facto della facto della facto della facto della facto della f	X			
	Vardenafil	×		X .			
Miscellaneous	Metaproterenol	X*					
	L	l	L	L			

*Denotes screen-only analysis.

Page 8 of 8